Yinuo Pang Selected Research

risankizumab

1/2022	Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
1/2022	Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
12/2021	Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study.
1/2021	Pharmacokinetic Comparability of Risankizumab Formulations in Prefilled Syringe and Auto-injector for Subcutaneous Injection.
1/2020	Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients.
12/2019	Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis.
10/2019	Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials.
1/2019	Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yinuo Pang Research Topics

Disease

5	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2021 - 01/2019
3	Crohn Disease (Crohn's Disease) 01/2022 - 12/2021
3	Heart Failure 11/2018 - 04/2015
2	Abdominal Pain (Pain, Abdominal) 01/2022 - 01/2022
1	Autoimmune Diseases (Autoimmune Disease) 01/2020
1	Body Weight (Weight, Body) 12/2019
1	Chronic Kidney Failure (Chronic Renal Failure) 04/2016
1	Hypersensitivity (Allergy) 01/2016

Drug/Important Bio-Agent (IBA)

8	risankizumabIBA 01/2022 - 01/2019
4	Monoclonal AntibodiesIBA 01/2021 - 10/2019
3	Interleukin-23 (Interleukin 23)IBA 12/2021 - 12/2019
3	human serelaxin proteinIBA 11/2018 - 04/2015
2	Pharmaceutical PreparationsIBA 01/2022 - 01/2016
2	InterleukinsIBA 01/2022 - 10/2019
2	Immunoglobulins (Immunoglobulin)IBA 01/2021 - 01/2020
2	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 01/2020 - 01/2019
2	AntibodiesIBA 01/2020 - 01/2016
2	Hormones (Hormone)IBA 04/2016 - 04/2015
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022
1	C-Reactive ProteinIBA 01/2020
1	Proteins (Proteins, Gene)FDA Link 01/2020
1	Serum AlbuminIBA 01/2020
1	CreatinineIBA 01/2020
1	Cytochrome P-450 CYP2C19IBA 01/2019
1	Caffeine (No Doz)FDA LinkGeneric 01/2019
1	EnzymesIBA 01/2019
1	Metoprolol (Toprol-XL)FDA LinkGeneric 01/2019
1	Midazolam (Versed)FDA LinkGeneric 01/2019
1	Omeprazole (Prilosec)FDA LinkGeneric 01/2019
1	Warfarin (Coumadin)FDA LinkGeneric 01/2019
1	Cytochrome P-450 CYP1A2 (CYP1A2)IBA 01/2019
1	Cytochrome P-450 CYP2D6 (CYP2D6)IBA 01/2019
1	Cytochrome P-450 CYP3AIBA 01/2019
1	Cytochrome P-450 CYP2C9IBA 01/2019
1	Peptides (Polypeptides)IBA 11/2018

Therapy/Procedure

2	Therapeutics 01/2022 - 01/2022
1	Intravenous Infusions 04/2016
1	Renal Dialysis (Hemodialysis) 04/2016